If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Jaypirca ™ (pirtobrutinib) tablets
50 mg,100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What should be monitored in patients when they are on Jaypirca™ (pirtobrutinib) treatment?
Patients being treated with Jaypirca (pirtobrutinib) should be monitored for infections, hemorrhage, cytopenia, atrial fibrillation and atrial flutter, and the development of second primary malignancies.
Monitoring During Pirtobrutinib Treatment
Patients being treated with pirtobrutinib should be monitored for
- atrial fibrillation and atrial flutter, and
- the development of second primary malignancies.1
In the event of an adverse reaction, pirtobrutinib can be
- dose reduced
- temporarily withheld, or
- permanently discontinued.1
Patients treated with pirtobrutinib should be monitored for signs and symptoms of infections. The signs and symptoms should be evaluated and treated promptly as medically appropriate. Patients should be counseled to report any signs or symptoms of infection (eg, fever, chills, and weakness).1
Prophylaxis, including vaccinations and antimicrobial prophylaxis, should be considered for patients who are at an increased risk for infections, including opportunistic infections.1
Patients treated with pirtobrutinib should be monitored for signs of bleeding.1
The risks and benefits of withholding pirtobrutinib treatment for 3-7 days pre-surgery and post-surgery depending upon the type of surgery and risk of bleeding should be considered during treatment with pirtobrutinib. The benefit-risk should also be considered in the event of co-administration of antithrombotic agents with pirtobrutinib.1
For patients treated with pirtobrutinib, complete blood counts should be monitored regularly during treatment.1
Atrial Fibrillation and Atrial Flutter
Patients treated with pirtobrutinib should be monitored for signs and symptoms of arrythmias (e.g., palpitations, dizziness, syncope, dyspnea) and managed appropriately. Patients should be counseled to report any signs of palpitations, dizziness, fainting, chest discomfort, and shortness of breath while on treatment.1
Second Primary Malignancies
Patients treated with pirtobrutinib should be monitored for the development of second primary malignancies. Patients should be counseled to use appropriate sun protection.1
Enclosed Prescribing Information
1Jaypirca [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
Date of Last Review: December 16, 2022